Dear stakeholders, For information, NICE has decided to defer the single technology appraisal of gefurulimab for treatment of antibody-positive generalised myasthenia gravis. This is due to a request received from the company, to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 12256
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 October 2025 | Suspended. Dear stakeholders, For information, NICE has decided to defer the single technology appraisal of gefurulimab for treatment of antibody-positive generalised myasthenia gravis. This is due to a request received from the company, to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 18 September 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual